Acquired resistance to targeted inhibitors of the MAPK pathway confers cross‐resistance to immunotherapy | Research Institute of Molecular Pathology (IMP)

Acquired resistance to targeted inhibitors of the MAPK pathway confers cross‐resistance to immunotherapy

23 April 2021
14:00
Zoom
Lisa Haas

Institute:: IMP - Obenauf Lab
Type:: PhD Defense
Location:: Zoom

Share

Facebook Twitter Google Plus LinkedIn